Biodesix Inc
BDSX
Market Cap$144.5M
Close$
Share Statistics
| Market cap | $144.50 Million |
|---|---|
| Enterprise Value | $178.91 Million |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-0.64 |
| Beta | 0.0 |
| Outstanding Shares | 114,685,542 |
| Avg 30 Day Volume | 252,448 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -2.77 |
|---|---|
| PEG | 5.03 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 3.64 |
| Enterprise Value to EBIT | -4.33 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.34 |
| Debt to Equity | 13.25 |
Revenue Sources
No data
ESG Score
No data
About Biodesix Inc
200 employeesBiodesix, Inc. operates as a biotechnology company. The Company offers non-small cell lung cancer pretreatment serum tests and laboratory testing. Biodesix provides diagnostic tools and equipment for blood and tissue analysis in the United States.